Doctors and drug companies

New England Journal of Medicine

Volumn 351, Issue 18, 2004, Pages 1885-1890

  Blumenthal, David ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG COST; DRUG INDUSTRY; DRUG MARKETING; HUMAN RELATION; MEDICAL PROFESSION; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; REVIEW; SOCIAL ASPECT; ARTICLE; CONFLICT OF INTEREST; ECONOMICS; ETHICS; GIFT GIVING; HEALTH CARE AND PUBLIC HEALTH; HUMAN; PHYSICIAN; PUBLIC RELATIONS; STANDARD; UNITED STATES;

HEALTH CARE AND PUBLIC HEALTH;

CONFLICT OF INTEREST; DRUG INDUSTRY; GIFT GIVING; HUMANS; INTERPROFESSIONAL RELATIONS; PHYSICIANS; UNITED STATES;

EID: 6944238651     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMhpr042734     Document Type: Review

References (36)

1. Quality of health care delivered to adults in the United States. N Engl J Med 2003;349:1866-8.
2. Relman AS, Angell M. America's other drug problem. The New Republic. December 16, 2002:27-41.
3. Levit K, Smith C, Cowan C, Sensenig A, Catlin A. Health spending rebound continues in 2002. Health Aff (Millwood) 2004;23(1): 147-59.
4. Petersen M. Suit says company promoted drug in exam room. New York Times. May 15, 2002:C1.
5. Dembner A. TAP officials on trial today in fraud case. Boston Globe. April 20, 2004:1.
6. Gilpin KN. Pfizer pays large fine to settle drug suit. International Herald Tribune. May 14, 2004:11.
7. Drugmakers' gifts to doctors finally get needed scrutiny. USA Today. October 14, 2002:A14.
8. Darves B. Too close for comfort? How some physicians are reexamining their dealings with drug detailers. ACP Observer. July-August 2003:1. (Philadelphia: American College of Physicians.)
9. Standards for commercial support. Chicago: Accreditation Council for Continuing Medical Education, 2004.
10. Coyle SL. Physician-industry relations. 1. Individual physicians. Ann Intern Med 2002;136:396-402.
11. PhRMA. PhRMA adopts new marketing code. April 19, 2002. (Accessed October 7, 2004, at http://www.phrma.org/mediaroom/press/releases/19.04.2002.390.cfm.)
12. Reinhardt UE. An information infrastructure for the pharmaceutical market. Health Aff (Millwood) 2004;23(1):107-12.
13. Katz D, Caplan AL, Merz JF. All gifts large and small: toward an understanding of the ethics of pharmaceutical industry gift-giving. Am J Bioeth 2003;3(3):39-46.
14. Moynihan R. Who pays for the pizza? Redefining the relationships between doctors and drug companies. 2. Disentanglement. BMJ 2003;326:1193-6.
15. Wazana A. Physicians and the pharmaceutical industry: is a gift everjust a gift? JAMA 2000;283:373-80.
16. Keim SM, Mays MZ, Grant D. Interactions between emergency medicine programs and the pharmaceutical industry. Acad Emerg Med 2004;11:19-26.
17. Komesaroff PA, Kerridge IH. Ethical issues concerning the relationships between medical practitioners and the pharmaceutical industry. Med J Aust 2002;176:118-21.
18. National survey of physicians. Part 2. Doctors and prescription drugs. Washington, D.C.: Kaiser Family Foundation, March 2002.
19. Ferguson RP, Rhim E, Belizaire W, Egede L, Carter K, Lansdale T. Encounters with pharmaceutical sales representatives among practicing internists. Am J Med 1999;107:149-52.
20. ACCME annual report data 2003. Chicago: Accreditation Council for Continuing Medical Education, 2003.
21. Relman AS. Separating continuing medical education from pharmaceutical marketing. JAMA 2001;285:2009-12.
22. Moynihan R. Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1. Entanglement. BMJ 2003;326:1189-92.
23. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 2002;287:612-7.
24. Studdert DM, Mello MM, Brennan TA. Financial conflicts of interest in physicians' relationships with the pharmaceutical industry - self-regulation in the shadow of federal prosecution. N Engl J Med 2004:351;1891-900.
25. Chren M. Interactions between physicians and drug company representatives. Am J Med 1999;107:182-3.
26. Brett AS, Burr W, Moloo J. Are gifts from pharmaceutical companies ethically problematic A survey of physicians. Arch Intern Med 2003;163:2213-8.
27. Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA 2003;290:252-5.
28. Watkins C, Moore L, Harvey I, Carthy P, Robinson E, Brawn R, Characteristics of general practitioners who frequently see drug industry representatives: national cross sectional study. BMJ 2003;326:1178-9.
29. Gibbons RV, Landry FJ, Blouch DL, et al. A comparison of physicians, and patients' attitudes toward pharmaceutical industry gifts. J Gen Intern Med 1998;13:1514.
30. Pear R. Drug industry is told to stop gifts to doctors. New York Times. October 1, 2002:A1.
31. Kowalczyk L. Drug companies' secret reports outrage doctors. Boston Globe. May 25, 2003:1.
32. Wager E. How to dance with porcupines: rules and guidelines on doctors' relations with drug companies. BMJ 2003;326:1196-8.
33. Rogers WA, Mansfield PR, Braunack-Mayer AJ, Jureidini JN. The ethics of pharmaceutical industry relationships with medical students. Med J Aust 2004;180:411-4.
34. Robeznieks A. States ask drug firms to report gifts to individual physicians. Chicago: American Medical News. March 1, 2004:1-2.
35. Grande D, Volpp K. Cost and quality of industry-sponsored meals for medical residents. JAMA 2003;290:1150-1.
36. Sorrell WH. Pharmaceutical marketing disclosures: report of Vermont Attorney General William H. Sorrell. Montpelier: State of Vermont Office of the Attorney General, February 2004.